Light from the IPO window

A slow season for biotech IPOs may be coming to an end. In the past two weeks, four biopharmas have filed for NASDAQ listings in which they’re seeking to raise $100 million or more. Two more filed during August for Hong Kong offerings to raise undisclosed amounts.

The latest prospectus, filed late Tuesday, is from BioAge Labs Inc., a Richmond, Calif.-based company whose APLNR agonist azelaprag is in clinical testing for obesity in separate combinations with approved GLP-1R agonists tirzepatide and semaglutide. BioAge entered the queue behind three biotechs that filed in August: MBX Biosciences Inc., Zenas BioPharma Inc. and Bicara Therapeutics Inc...